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Objectives. This study tested the hypothesis that metoprolol
restores the reduction of the inotropic effect of the cyclic adeno-
sine monophosphate (cAMP)-phosphodiesterase inhibitor milri-
none, which is cAMP dependent but beta-adrenoceptor indepen-
dent.
Background. Treatment with beta-adrenergic blocking agents
has been shown to lessen symptoms and improve submaximal
exercise performance and left ventricular ejection fraction in
patients with heart failure. Restoration of the number of down-
regulated beta-adrenoceptors has been suggested to be one mech-
anism of beta-blocker effectiveness. However, the reversal of
postreceptor events, namely, an increase in inhibitory G-protein
alpha-subunit concentrations, could also play a role.
Methods. Fifteen patients with heart failure due to dilated
cardiomyopathy (left ventricular ejection fraction 24.6 6 1.5%
[mean 6 SD], New York Heart Association functional class II or
III) were treated with metoprolol (maximal dose 50 mg three
times daily) for 6 months. Before and after metoprolol treatment,
inotropic responses to milrinone (5 to 10 mg/kg body weight per
min) were measured echocardiographically. For comparison, re-
sponses to milrinone were determined under control conditions
and after accelerated application of 150 mg of metoprolol to
inactivate beta-adrenoceptors in subjects with normal left ventric-
ular function.
Results. In subjects with normal left ventricular function,
treatment with metoprolol did not alter the increase in fractional
shortening or pressure/dimension ratio of circumferential fiber
shortening after application of milrinone. In patients with heart
failure, treatment with metoprolol significantly increased left
ventricular ejection fraction, fractional shortening and submaxi-
mal exercise tolerance and reduced heart rate, plasma norepi-
nephrine concentrations and functional class. After metoprolol
treatment, milrinone increased fractional shortening but had no
effect before beta-blocker treatment.
Conclusions. Milrinone increases inotropic performance inde-
pendently of beta-adrenoceptors in vivo. Metoprolol treatment
restores the blunted inotropic response to milrinone in patients with
heart failure, indicating that postreceptor events (e.g., increase in
inhibitory G-proteins) are favorably influenced. This mechanism
could contribute to the beneficial effects observed in the study
patients and represents an important mechanism of how beta-
blocker treatment influences the performance of the failing heart.
(J Am Coll Cardiol 1997;30:992–6)
©1997 by the American College of Cardiology
Desensitization of beta-adrenoceptor–adenylyl cyclase signal
transduction is recognized as an important mechanism contrib-
uting to impaired contractility in the failing human heart (1–3).
Beta1-adrenoceptors are downregulated, leading to impaired
positive inotropic effects of beta-adrenoceptor agonists (1–3).
However, the effects of cyclic adenosine monophosphate
(cAMP)–phosphodiesterase inhibitors, which bypass beta-
adrenoceptors and inhibit the breakdown of cAMP, are also
impaired (4,5) and are due to postreceptor alterations in the
failing heart (2). This alteration has been identified as an
increase in inhibitory G-protein alpha-subunits (Gia) (6–8).
Experimental studies have shown (9,10) that both the reduc-
tion of beta-adrenoceptors and the increase of Gia are induced
by catecholamines. Therefore, a reversal of these defects could
contribute to a functional improvement of the failing heart.
Long-term beta-adrenergic blocking agent treatment has
been shown (11–13) to be beneficial in patients with heart
failure due to dilated cardiomyopathy in terms of improving
left ventricular ejection fraction, submaximal exercise toler-
ance (11–13) and, possibly, prognosis (11,14). Treatment with
metoprolol has been shown (15,16) to increase the number of
beta-adrenoceptors, correlating to an improvement in left
ventricular ejection fraction. However, treatment with the
vasodilating beta-blocker carvedilol did not increase beta-
adrenoceptors despite a similar increase in left ventricular
ejection fraction. Therefore, it is likely that improvement of
postreceptor defects is also an important contributor to im-
proved cardiac function.
In the present study, we took advantage of the beta-
adrenoceptor–independent but cAMP-dependent positive ino-
tropic effects of milrinone in healthy volunteers (normal left
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ventricular function) and in patients with moderate heart
failure (left ventricular ejection fraction 25% to 42%). To
investigate the effects of beta-blocker treatment on postrecep-
tor mechanisms, we studied echocardiographic variables of
contractility before and after metoprolol treatment for 6
months.
Methods
Patients. Patients with chronic, stable left-sided heart fail-
ure due to dilated cardiomyopathy (13 men, 2 women; mean
[6SD] age 54.9 6 2.1 years, range 42 to 72 years) were
investigated. All patients had dilated cardiomyopathy. Signifi-
cant coronary artery disease was excluded by coronary angiog-
raphy in all patients. In addition, seven male volunteers (mean
age 32.4 6 4 years, range 21 to 44) were investigated as healthy
control subjects.
Measurement of contractility in vivo by echocardiography.
Two-dimensionally guided M-mode echocardiography in the
short-axis view was performed transthoracically using a me-
chanical sector scanner (Vingmed CFM 750, Sonotron) with a
3.25-MHz transducer. All recordings were made by the same
investigator (A.S.) and were evaluated independently by two
principal investigators (H.D., M.B.) from the echocardiogra-
phy laboratory. End-diastolic diameter (EDD) and end-
systolic left ventricular diameter (ESD) were measured as the
mean of five cardiac cycles according to standard guidelines
(17). Fractional shortening was calculated as (EDD 2 ESD)/
EDD 3 100. To control for effects of potentially different
afterload conditions, the pressure/dimension ratio (P/D) was
calculated as the ratio of systolic blood pressure to end-
diastolic dimension. In previous studies, intraobserver variabil-
ity was ,3% (18), and interobserver variability did not exceed
4.6% (19). The latter data fit well with those previously
reported for reproducibility guidelines for M-mode echocardi-
ography (20,21). Systolic, diastolic and mean arterial blood
pressures were measured in the right arm by an automated
sphygmomanometer (Critikon, Dinamap). Heart rate was ob-
tained from simultaneous electrocardiographic recordings.
Study protocol. Echocardiographic investigations were
performed before and after 6 months of metoprolol therapy in
patients with heart failure. Therapy was started with a dose of
10 mg of metoprolol once daily, which was doubled every 2
weeks after confirming the absence of adverse drug reactions,
such as clinically significant bradycardia, syncope, arterial
hypotension or signs of pulmonary congestion. The maximal
dosage of metoprolol in this study was 50 mg three times daily.
At echocardiography a cannula was inserted into a left forearm
vein. After 15 min in the supine position, basal recordings were
taken. A continuous intravenous infusion of milrinone (Sanofi
Winthrop GmbH, Munich, Germany) was started with 5 mg/kg
body weight per min for 10 min and was increased to 7.5 and
10 mg/kg per min for 5 min each. Higher dosages were not
applied to avoid cAMP-triggered arrhythmias. Echocardio-
graphic and blood pressure recordings were taken at rest and
1 min before increasing the respective dose. At the beginning
of the study and after 6 months, radionuclide ventriculography
was performed at rest and under a moderate, submaximal
workload of 50 W of bicycle exercise in the supine position.
Healthy male volunteers underwent the same studies as the
patients with heart failure. The effect of milrinone was studied
under control conditions and after 150 mg of oral metoprolol
within 10 h of echocardiography.
This study was in accordance with the declaration of
Helsinki and was approved by the local ethics committee.
Written informed consent was given by each patient.
Statistical analysis. The response to milrinone in the pres-
ence and absence of metoprolol was compared by two-way
analysis of variance (ANOVA). Normal distribution of the
sample was assessed by the Kolmogorov-Smirnov goodness of
fit test. Probability values ,0.05 were considered significant.
Results are reported as mean value 6 SD, unless otherwise
indicated. Statistical analysis was performed using the SPSS for
Windows package (version 7.0).
Results
Effects of milrinone on contractility. We set out to deter-
mine whether the effects of milrinone on contractility in vivo
were independent of intact beta-adrenoceptors. Volunteers
were studied under control conditions and after a cumulative
metoprolol oral dose of 150 mg within 10 h of the investigation.
Echocardiographic studies were performed during infusion of
increasing concentrations of milrinone. The increase in frac-
tional shortening was similar to that during application of the
phosphodiesterase inhibitor under control conditions or after
pretreatment with metoprolol (Fig. 1A). Similar results were
obtained when the systolic P/D ratio was determined (control:
3.9 6 0.4 to 4.8 6 0.7 mm Hg/mm, p , 0.05; metoprolol: 3.5 6
0.4 to 4.4 6 0.9 mm Hg/mm, p , 0.05). The milrinone doses
used did not significantly reduce mean arterial blood pressure
and instantaneous resistance (not shown). In contrast, the
effect of dobutamine was completely antagonized by treatment
with metoprolol (Fig. 1B). Taken together, the data show that
the effects of milrinone on contractility are independent of
intact beta-adrenoceptors, because under these conditions the
effect of dobutamine is markedly attenuated.
Effects of metoprolol in patients with heart failure. To
investigate the effects of metoprolol treatment on milrinone
effects on contractility, 15 patients with moderate heart failure
were treated for 6 months with metoprolol (maximal dose
Abbreviations and Acronyms
ANOVA 5 analysis of variance
cAMP 5 cyclic adenosine monophosphate
Gia 5 inhibitory G-protein alpha-
subunit
MDC 5 Metoprolol in Dilated
Cardiomyopathy
P/D 5 pressure/dimension ratio
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50 mg three times daily). The clinical state of the patients
improved from a mean functional class 2.9 6 0.4 to 1.4 6 0.5,
and exercise tolerance changed from 62 6 3 to 99 6 5 W.
Metoprolol treatment reduced heart rate from 91 6 10 to 71 6
9 beats/min and increased mean arterial blood pressure
(mean 6 SEM). In addition, left ventricular ejection fraction
and fractional shortening were significantly increased. Neuro-
hormonal activation, as judged from plasma norepinephrine
concentrations, was reduced. Data are summarized in Table 1.
To investigate whether metoprolol treatment affects the beta-
adrenoceptor–independent effects of milrinone, dose-
dependent effects were studied before and after 6 months of
metoprolol treatment.
As shown in Figure 2, basal fractional shortening and P/D
ratios were significantly increased after 6 months of metoprolol
treatment. Before treatment with the beta-blocker, milrinone
did not significantly increase fractional shortening (Fig. 2) or
the P/D ratio (1.6 6 0.3 vs. 1.6 6 0.3 mm Hg/mm at 10 mg/kg
per min, p . 0.05, two-way ANOVA). However, after 6
months of metoprolol treatment, fractional shortening at rest
had increased significantly during intravenous application of
milrinone (22.5 6 1.9% to 29.0 6 2.7%, p , 0.05, two-way
ANOVA). Metoprolol treatment and short-term milrinone
application were determined to be factors that each signifi-
cantly influenced fractional shortening in an independent
manner (two-way ANOVA). P/D ratio values were only slightly
increased by milrinone, from 2.1 6 0.4 mm Hg/mm (control) to
2.4 6 0.6 mm Hg/mm (p 5 NS) after metoprolol treatment.
Taken together, long-term metoprolol treatment in patients
with heart failure restores the cAMP-dependent inotropic
effect of the cAMP–phosphodiesterase inhibitor milrinone,
which is independent of beta-adrenoceptors.
Discussion
The present study investigated whether long-term beta-
blocker therapy with metoprolol is capable of restoring the
cAMP-dependentbutbeta-adrenoceptor–independent inotrop-
ic effects of milrinone in patients with heart failure. Metoprolol
treatment for 6 months increased left ventricular ejection
fraction, exercise tolerance and functional class. In addition,
metoprolol reduced serum norepinephrine concentrations.
These effects were accompanied by a restoration of the ino-
tropic effects of milrinone, which were demonstrated to be
independent of the intactness of beta-adrenoceptor signaling.
Figure 1. Change in fractional shortening (FS) under control condi-
tions (C) or after treatment with metoprolol (M) (150 mg orally within
10 h of echocardiography) after application of milrinone (A) or
dobutamine (B) in healthy volunteers.




LVEF (%)* 24.6 6 1.5 40.3 6 3.6 ,0.01
FS (%) 13.2 6 1.0 22.5 6 1.9 ,0.001
P/D (mm Hg/mm) 1.6 6 0.3 2.1 6 0.4 ,0.0006
Ex tolerance (W) 62 6 3 99 6 5 ,0.001
MAP (mm Hg) 86.5 6 2.4 99.1 6 5.2 ,0.01
HR (beats/min) 91 6 10 71 6 9 ,0.01




NE (nmol/liter) 3.8 6 0.5 2.7 6 0.4 ,0.05
BW (kg) 76 6 15 83 6 16 ,0.05
*Determined by radionuclide ventriculography. Data presented are mean
value 6 SD or number of patients. BW 5 body weight; Ex 5 exercise; FS 5
fractional shortening; func 5 functional; HR 5 heart rate; LVEF 5 left
ventricular ejection fraction; MAP 5 mean arterial pressure; NE 5 norepineph-
rine; NYHA 5 New York Heart Association; P/D 5 pressure/dimension ratio.
Figure 2. Fractional shortening (FS) after application of milrinone in
patients with heart failure before (Control) or after 6 months of
metoprolol treatment.
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Treatment with metoprolol. Fifteen patients with dilated
cardiomyopathy and moderate heart failure were treated ac-
cording to an accelerated protocol of the Metoprolol in
Dilated Cardiomyopathy (MDC) trial (13). Metoprolol pro-
duced a similar frequency reduction and a slightly more
pronounced effect on left ventricular ejection fraction than that
observed in the MDC trial. The mean metoprolol doses
achieved in the present study were slightly higher than those
achieved in the MDC trial, which could explain the slightly
better effect on left ventricular ejection fraction. Taken to-
gether, the patient group studied and the effects of treatment
closely resemble those of the MDC trial.
One important mechanism of contractile dysfunction in
heart failure is the desensitization of beta-adrenergic signal
transduction mechanisms (1–3). The number of beta-
adrenoceptors has been reported to be reduced at the protein
(1–3) and mRNA levels (22). The remaining receptors are
presumably uncoupled (3) by an increase in activity and
mRNA of the beta-adrenoceptor kinase (22).
Mechanisms of beta-adrenergic desensitization. These al-
terations produce a strong impairment of the positive inotropic
effects of beta-adrenoceptor agonists in vitro (1–3) and in vivo
(23). However, the positive inotropic effects of cAMP–
phosphodiesterase inhibitors are also reported to be reduced
(4,5).
As the mechanism for this reduced effectiveness, an in-
crease in Gia on protein (6–8) and mRNA levels (24) has been
reported by several groups. In pertussis toxin–treated mem-
branes from failing hearts, the depressed basal and guanine
nucleotide–stimulated adenylyl cyclase was reported to be
restored by pertussis toxin, which inactivates Gia (7). In
addition, in isolated cardiomyocytes from failing hearts, the
effects of the beta-adrenoceptor agonist isoproterenol were
restored to values similar to those observed in cardiomyocytes
from nonfailing hearts (25). These studies provided strong
biochemical and functional evidence for a significant contribu-
tion of Gia to the beta-adrenergic signal transduction defect in
the failing heart by depressing basal cAMP formation (26).
The reduction of the milrinone effects on force of contraction
is closely correlated to the increase in Gia protein concentra-
tions, as shown by in vitro studies (2). Finally, the positive
inotropic effect of milrinone is restored when basal cAMP
formation is enhanced by low concentrations of isoprenaline
(27) or forskolin (5). Therefore, the reduced basal cAMP
content due to elevated Gia is most likely responsible for the
reduced effects of cAMP–phosphodiesterase inhibitors like
milrinone. The other components of the adenylyl cyclase
system, namely, the stimulatory G-protein alpha-subunits
(Gsa), and the catalytic activity of adenylyl cyclase have been
shown to be unchanged (2,7,28). Hitherto, it was unknown
whether the increase in Gia could be pharmacologically mod-
ulated in humans.
Desensitization of beta-adrenergic signal transduction can
be induced by treatment of cultured neonatal rat cardiomyo-
cytes with norepinephrine in vitro (9). In these studies, the
mechanism was also a decrease in beta-adrenoceptors and an
increase in Gia. The effects could be antagonized by applica-
tion of beta-blockers but not by the alpha-blocker prazosin,
showing that the increase in Gia and beta-adrenoceptor down-
regulation is mediated by stimulation of beta-adrenoceptors
(9). Mu¨ller et al. (29) consistently reported in nuclear runon
assays an increase in the transcriptional activity of the Gia2
gene in rats treated with isoprenaline. Thus, it is very likely that
this adrenergic desensitization in the human failing heart is
induced in general by the sympathetic alteration and in partic-
ular by the local norepinephrine release with consecutive
beta-adrenoceptor stimulation in the failing heart.
Effects of beta-blocker treatment. From these studies on
the pathophysiology of signal transduction in heart failure, it is
tempting to speculate that beta-blockers, at least in part, can
restore receptor and postreceptor defects. Heilbrunn et al. (15)
reported that the increase in left ventricular ejection fraction
after beta-blocker therapy with metoprolol for 6 months was
accompanied by an increase in beta-adrenoceptor density, as
judged from radioligand binding studies in myocardial biopsy
specimens. In these patients, the inotropic effect of the beta-
adrenoceptor agonist on the force of contraction, determined
after discontinuation of beta-blocker therapy, was restored. In
the present study, we addressed the question of whether
postreceptor mechanisms, presumably the result of an increase
in Gia content, are also restored by beta-blocker treatment.
Determination of Gia content with immunochemical tech-
niques is difficult in myocardial biopsy samples because larger
amounts of tissue are required to obtain reliable results.
Quantitative polymerase chain reaction is hampered by the
great homology between the different G-protein subtypes.
Therefore, we studied the effects of milrinone in vivo, which is
clearly dependent on postreceptor mechanisms and indepen-
dent of the function of beta-adrenoceptors. The restoration of
inotropic responses to milrinone provides strong evidence that
a postreceptor event involving adenylyl cyclase is favorably
influenced by metoprolol treatment. Interestingly, the beta-
adrenoceptor antagonist carvedilol increased left ventricular
ejection fraction similar to metoprolol but had no effect on
beta-adrenoceptor density; however, myocardial beta-
adrenoceptor density was almost doubled after 6 months of
metoprolol treatment in patients with heart failure (16). These
data suggest that beta-blockers also target postreceptor events
not just receptors. During the preparation of the present
clinical study, a report appeared that investigated the amount
of Gia-related pertussis toxin substrates in the myocardial
biopsy specimens of patients before and after 3 months of
metoprolol treatment (30). Treatment with metoprolol in-
creased oxygen uptake at the anaerobic threshold, increased
beta1-adrenoceptors and reduced Gia-related pertussis toxin
substrates (30). Therefore, the present observational data
suggest that the reduction of Gia also has functional relevance
for inotropic interventions. Consistent with the restoration of
postreceptor alterations, reported to be induced by beta-
adrenoceptor stimulation (10,29), the present study and previ-
ous investigations in patients with dilated cardiomyopathy (31)
found reduced norepinephrine plasma concentrations after
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beta-blocker treatment. In addition, the present findings could
have important implications for the treatment of heart failure
with cAMP–phosphodiesterase inhibitors. Clinical trials of
milrinone have been negative for improved survival (32). A
proarrhythmic potency and a positive chronotropic effect in the
presence of a reduced inotropic efficacy have both been
mentioned as a reason for the negative results. If concomitant
beta-blocker treatment can prevent the former adverse effects
(in partial or positive chronotropism) and can restore the
inotropic efficacy of cAMP-phosphodiesterase inhibitors by
reversing postreceptor alterations, combination therapy with
cAMP–phosphodiesterase inhibitors and beta-blockers could
be used to treat heart failure and would be worthwhile to
investigate.
Conclusions. Metoprolol treatment restores cAMP-depen-
dent positive inotropic effects independent of beta-adreno-
ceptors. This restoration most likely involves a modulation at
the level of inhibitory G-proteins. These data suggest a new
mechanism to explain the effect of beta-blockers on cardiac
performance in patients with heart failure.
The expert assistance of Bodo Cremers, MS is gratefully acknowledged.
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